Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT ID: NCT06795113
Last Updated: 2025-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2013-06-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
NCT04317313
Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma
NCT06737835
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
NCT05113576
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
NCT01410630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lesions were manually delineated, and software was used to automatically calculate PET/CT parameters such as SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for primary and metastatic lesions based on 18F-FDG PET/CT. Clinical data for all patients were collected from their medical records, including age, gender, LDH levels, B symptoms, extranodal involvement, IPI score, presence of bulky disease, pathological subtype, and treatment regimen.
Each patient's end-of-treatment PET/CT was compared with baseline PET/CT based on the Lugano criteria to evaluate treatment response, and the results were recorded in Group A. Correspondingly, the end-of-treatment PET/CT was also compared with interim PET/CT to derive a new treatment response evaluation, and the results were recorded in Group B. The treatment response evaluations from Groups A and B were then compared. Statistical analysis was performed to identify patients with inconsistent treatment response evaluations between the two groups. Additionally, it was recorded whether the treatment plan for each patient was altered at the end of first-line therapy based on the treatment response evaluation from Group B.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Modeling group, 2000 patients
clinicopathologic feature, post-treatment efficacy, extracted from the electronic medical record system: demographic characteristics (gender, age, ethnicity, family history, etc.), laboratory test results (complete blood count, blood biochemistry), nasopharyngoscopy, pathology, and nuclear medicine examination reports (PET/CT, PET/MR, etc.), tumor characteristics (tumor size, tumor invasion status, lymph node involvement, staging), and treatment plans.
No interventions assigned to this group
Validation group, 2000 patients
clinicopathologic feature, post-treatment efficacy, extracted from the electronic medical record system: demographic characteristics (gender, age, ethnicity, family history, etc.), laboratory test results (complete blood count, blood biochemistry), nasopharyngoscopy, pathology, and nuclear medicine examination reports (PET/CT, PET/MR, etc.), tumor characteristics (tumor size, tumor invasion status, lymph node involvement, staging), and treatment plans.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Underwent 18F-FDG PET/CT imaging before, during, and after treatment
3. Treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
West China Hospital
OTHER
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GUO RUI
Deputy Chief Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RuijinH 2025-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.